WealthBridge Capital Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.32M Buy
13,209
+89
+0.7% +$19.1K 0.66% 30
2026
Q1
$2.85M Buy
13,120
+85
+0.7% +$18.9K 0.66% 32
2025
Q4
$2.98M Sell
13,035
-57
-0.4% -$13K 0.68% 33
2025
Q3
$3.03M Buy
13,092
+292
+2% +$59.5K 0.71% 33
2025
Q2
$2.38M Buy
12,800
+262
+2% +$48.7K 0.6% 41
2025
Q1
$2.63M Sell
12,538
-35
-0.3% -$6.8K 0.74% 29
2024
Q4
$2.23M Buy
12,573
+317
+3% +$58.3K 0.62% 39
2024
Q3
$2.42M Buy
12,256
+972
+9% +$181K 0.69% 33
2024
Q2
$1.94M Sell
11,284
-243
-2% -$40.3K 0.64% 37
2024
Q1
$2.1M Sell
11,527
-9
-0.1% -$1.55K 0.71% 34
2023
Q4
$1.79M Sell
11,536
-20
-0.2% -$2.92K 0.67% 36
2023
Q3
$1.72M Sell
11,556
-215
-2% -$31.6K 0.71% 32
2023
Q2
$1.59M Buy
11,771
+61
+0.5% +$8.95K 0.63% 34
2023
Q1
$1.87M Buy
11,710
+180
+2% +$27.5K 0.74% 33
2022
Q4
$1.86M Buy
11,530
+454
+4% +$69.6K 0.78% 32
2022
Q3
$1.7M Hold
11,076
0.72% 32
2022
Q2
$1.7M Buy
11,076
+358
+3% +$54.7K 0.72% 32
2022
Q1
$1.74M Buy
10,718
+756
+8% +$110K 0.65% 33
2021
Q4
$1.35M Buy
9,962
+53
+0.5% +$6.26K 0.5% 46
2021
Q3
$1.07M Buy
9,909
+44
+0.4% +$5.03K 0.4% 53
2021
Q2
$1.11M Sell
9,865
-97
-1% -$10.9K 0.4% 54
2021
Q1
$1.08M Buy
9,962
+50
+0.5% +$5.35K 0.44% 52
2020
Q4
$1.06M Buy
9,912
+4
+0% +$384 0.46% 50
2020
Q3
$868K Buy
9,908
+103
+1% +$9.7K 0.45% 50
2020
Q2
$963K Buy
9,805
+207
+2% +$18.2K 0.55% 43
2020
Q1
$731K Sell
9,598
-123
-1% -$10.5K 0.51% 48
2019
Q4
$861K Buy
9,721
+28
+0.3% +$2.33K 0.56% 48
2019
Q3
$734K Sell
9,693
-397
-4% -$27.2K 0.53% 47
2019
Q2
$930K Sell
10,090
-220
-2% -$17.3K 0.85% 33
2019
Q1
$803K Buy
10,310
+220
+2% +$18K 0.51% 41
2018
Q4
$930K Buy
+10,090
New +$887K 0.71% 33

Other funds holding ABBV

WealthBridge Capital Management's ABBV Position: Q2 2026 in Review

WealthBridge Capital Management increased its AbbVie (ABBV) stake by 0.68% in Q2 2026, buying an estimated $19.1K and bringing the position to 13,209 shares worth $3.32M. The position accounts for 0.66% of the portfolio, ranked #30.

WealthBridge Capital Management first reported a position in ABBV in Q4 2018 and has held it in 31 quarters since. 4,195 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • WealthBridge Capital Management held 13,209 shares of AbbVie worth $3.32M as of Q2 2026.
  • WealthBridge Capital Management bought 89 AbbVie shares in Q2 2026, an estimated $19.1K.
  • AbbVie made up 0.66% of WealthBridge Capital Management's portfolio in Q2 2026, its #30 holding.
  • WealthBridge Capital Management first reported a position in AbbVie in Q4 2018 and has held it in 31 quarters since.
  • 4,195 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on WealthBridge Capital Management's 13F filing for Q2 2026, filed 24 Jul 2026.